Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BY-NC 4.0Journal of Hepatocellular Carcinoma

Conversion Surgery After HAIC-Based Combination Therapy with Targeted Therapy and Immune Checkpoint Inhibitors for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study

  • Xiaolong Zhang1
  • Jun Hu2
  • Haoming Lan2
  • Xianfeng Shen2
  • Meng Zhou2
  • Youyou Tian3
  1. 1Department of Radiology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, People’s Republic of China
  2. 2Department of Hepatopancreatobiliary Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, People’s Republic of China
  3. 3Department of Outpatient, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, People’s Republic of China
Read full textPDFDOICite

Abstract

Background: For selected patients whose initially unresectable hepatocellular carcinoma (HCC) responds to hepatic arterial infusion chemotherapy (HAIC)-based combination treatment, conversion surgery may provide an opportunity for curative-intent management. We quantified the frequency of conversion surgery, examined factors associated with surgical conversion, and assessed survival and pathological outcomes using analyses that accounted for immortal time bias.

Methods: We conducted a single-center retrospective cohort study of 216 patients with initially unresectable HCC who received HAIC together with targeted therapy and immune checkpoint blockade from September 2020 through June 2023. The relationship between conversion surgery and survival was examined with time-dependent Cox regression and a prespecified 180-day landmark analysis. Two hepatopathologists independently assessed the pathological response.

Results: 47 (21.8%) patients underwent conversion surgery, and 16 (34.0%) achieved pathological complete response (pCR). Median overall survival (OS) was 22.7 months (95% confidence interval [CI], 21.1–25.8), and median progression-free survival (PFS) was 13.7 months (95% CI, 10.9–16.2). In adjusted 180-day landmark analyses including 211 patients for OS and 166 patients for PFS, conversion surgery was associated with lower hazards of death (hazard ratio [HR], 0.30; 95% CI, 0.16–0.59; P < 0.001) and progression or death (HR, 0.32; 95% CI, 0.16–0.64; P = 0.001); time-dependent Cox models produced consistent findings. Albumin ≥ 35 g/L was associated with higher odds of conversion surgery (odds ratio [OR], 5.47; 95% CI, 1.75–17.06), whereas multifocal tumors were associated with lower odds (OR, 0.13; 95% CI, 0.06–0.29). Among resected patients, pCR was associated with favorable postoperative outcomes in exploratory unadjusted analyses.

Conclusion: 47 of 216 patients (21.8%) underwent conversion surgery after HAIC-based combination therapy. Conversion surgery was associated with favorable OS and PFS after accounting for treatment timing. However, causal inference remains limited by residual confounding and treatment-selection bias in this retrospective study. The prognostic value of pCR requires validation in larger prospective cohorts.

Related

  1. Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC, Bevacizumab, and Tislelizumab: A Case Report
    Qing Ye, Jiamin Wang, Junming He +3
    Clinical Case ReportsPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records
    Canchao Sun, Juan Xu, Tiye Sun
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Survival outcomes of radiotherapy in elderly patients with unresectable stage III hepatocellular carcinoma: a population-based retrospective cohort study
    Shuai Hao, Jingjing Tuo, Ziyi Xie +5
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Muscle strength and muscle mass phenotypes and survival in unresectable hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy-based combination therapy
    Chan Su, Guibao Ji, Xinze Wang +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  5. Resection rates after conversion therapy for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Xiaobo Ouyang, Ji Li, Po Liang +4
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{zhang2026conversion,
  title = {{Conversion Surgery After HAIC-Based Combination Therapy with Targeted Therapy and Immune Checkpoint Inhibitors for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study}},
  author = {Xiaolong Zhang and Jun Hu and Haoming Lan and Xianfeng Shen and Meng Zhou and Youyou Tian},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  month = oct,
  doi = {10.2147/jhc.s644129},
  url = {https://doi.org/10.2147/jhc.s644129},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Conversion Surgery After HAIC-Based Combination Therapy with Targeted Therapy and Immune Checkpoint Inhibitors for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
AU  - Xiaolong Zhang
AU  - Jun Hu
AU  - Haoming Lan
AU  - Xianfeng Shen
AU  - Meng Zhou
AU  - Youyou Tian
PY  - 2026
DA  - 2026/10/27
JO  - Journal of Hepatocellular Carcinoma
DO  - 10.2147/jhc.s644129
UR  - https://doi.org/10.2147/jhc.s644129
AB  - Background: For selected patients whose initially unresectable hepatocellular carcinoma (HCC) responds to hepatic arterial infusion chemotherapy (HAIC)-based combination treatment, conversion surgery may provide an opportunity for curative-intent management. We quantified the frequency of conversion surgery, examined factors associated with surgical conversion, and assessed survival and pathological outcomes using analyses that accounted for immortal time bias.  Methods: We conducted a single-center retrospective cohort study of 216 patients with initially unresectable HCC who received HAIC together with targeted therapy and immune checkpoint blockade from September 2020 through June 2023. The relationship between conversion surgery and survival was examined with time-dependent Cox regression and a prespecified 180-day landmark analysis. Two hepatopathologists independently assessed the pathological response.  Results: 47 (21.8%) patients underwent conversion surgery, and 16 (34.0%) achieved pathological complete response (pCR). Median overall survival (OS) was 22.7 months (95% confidence interval [CI], 21.1–25.8), and median progression-free survival (PFS) was 13.7 months (95% CI, 10.9–16.2). In adjusted 180-day landmark analyses including 211 patients for OS and 166 patients for PFS, conversion surgery was associated with lower hazards of death (hazard ratio [HR], 0.30; 95% CI, 0.16–0.59; P < 0.001) and progression or death (HR, 0.32; 95% CI, 0.16–0.64; P = 0.001); time-dependent Cox models produced consistent findings. Albumin ≥ 35 g/L was associated with higher odds of conversion surgery (odds ratio [OR], 5.47; 95% CI, 1.75–17.06), whereas multifocal tumors were associated with lower odds (OR, 0.13; 95% CI, 0.06–0.29). Among resected patients, pCR was associated with favorable postoperative outcomes in exploratory unadjusted analyses.  Conclusion: 47 of 216 patients (21.8%) underwent conversion surgery after HAIC-based combination therapy. Conversion surgery was associated with favorable OS and PFS after accounting for treatment timing. However, causal inference remains limited by residual confounding and treatment-selection bias in this retrospective study. The prognostic value of pCR requires validation in larger prospective cohorts.
SN  - 2253-5969
ER  -